Status: Recruiting
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.
Participants needed: 100
Trial details
Age: 22-80Biological sex: AllType: InterventionalSponsor: Pulse Biosciences, Inc.Updated: Apr 15, 2026Locations: 3
Eligibility criteria
Participant is willing and able to provide voluntary, written informed consent t... [+10]
Participant has an implantable electronic medical device. (i.e., pacemaker, impl... [+15]